source
- FDA updates guidance for generic makers of top GLP-1 weight-loss drugsThe FDA has released a revised draft guidance aimed at companies that want to develop generic versions of leading weight-loss medications. The update focuses on products such as Eli Lilly's Zepbou…
- FDA finds Capricor's Duchenne stem cell therapy failed to meet Phase 3 goals, contradicting company claimsThe U.S. Food and Drug Administration announced that the stem cell treatment from Capricor Therapeutics did not achieve the primary objectives in its Phase 3 trial for Duchenne muscular dystrophy.…